X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Allogeneic iPSC-derived Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: UTokyo Innovation Platform
Deal Size: $37.0 million Upfront Cash: Undisclosed
Deal Type: Series C Funding June 11, 2021
Details:
Heartseed plans to use the new funds to accelerate the initiation of global clinical trial of our lead asset, HS-001 for HF as well as to confirm its proof of concept in Phase 1/2 LAPiS study in Japan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Allogeneic iPSC-derived Cardiomyocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: HS-001
Highest Development Status: IND Enabling Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $598.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration June 01, 2021
Details:
HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells. Heartseed is planning to initiate a phase 1/2 clinical trial in Japan in the second half of 2021.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
